Estelle Erkner
Tuebingen, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Characterizing the impact of MLL fusion variants and fusion partners on leukemia plasticity using a human CRISPR-engineered MLL-rearranged leukemia model.
Journal: Neoplasia (New York, N.Y.)
Published: February 25, 2026
Only Infant MLL-Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib.
Journal: International journal of molecular sciences
Published: September 29, 2024
Protocol for CRISPR-Cas9-mediated induction of KMT2A rearrangements in cell line and umbilical cord blood hematopoietic stem and progenitor cells.
Journal: STAR protocols
Published: August 01, 2024
Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype.
Journal: Frontiers in oncology
Published: November 06, 2023
Uncovering NOTCH1 as a Promising Target in the Treatment of MLL-Rearranged Leukemia.
Journal: International journal of molecular sciences
Published: August 29, 2023
The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia.
Journal: Oncogene
Published: June 08, 2023
Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Journal: Neoplasia (New York, N.Y.)
Published: February 06, 2023
Cleavage of the vaspin N-terminus releases cell-penetrating peptides that affect early stages of adipogenesis and inhibit lipolysis in mature adipocytes.
Journal: Adipocyte
Published: April 19, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026